www.fdanews.com/articles/108370-phase-iib-pancreatic-cancer-trial-commences-for-psivida-product
Phase IIb Pancreatic Cancer Trial Commences for pSivida Product
July 8, 2008
A potential new brachytherapy treatment for inoperable pancreatic cancer is being studied in pSivida’s newly initiated Phase IIb clinical trial.
BrachySil is a combination of BioSilicon, a proprietary porous silicon, and the isotope phosphorus, a proven anti-cancer therapeutic. It can be delivered by endoscopic ultrasound, the company said.
The study will determine the safety of escalating radiation doses of the product.